Today the Department of Transportation amended its drug panel to include opioids effective January 1, 2018. DOT’s drug testing program will now include testing for hydrocodone, hydromorphone, oxymorphone, and oxycodone. The addition of hydrocodone, hydromorphone, oxymorphone, and oxycodone to the drug panel is in response to the current opioid crisis. These four semi-synthetic opioids have been added to provide consistency as mandated by Federal statute, OTETA, and applies not only to specimen testing validity values but also to initial and confirmatory testing values. The revision of the drug-testing panel harmonizes DOT regulations with the revised (non-DOT) HHS Mandatory Guidelines recently established by the U.S. Department of Health and Human Services for Federal drug-testing programs for urine testing.
To learn more….link to federal register: https://www.federalregister.gov/documents/2017/11/13/2017-24397/procedures-for-transportation-workplace-drug-and-alcohol-testing-programs-addition-of-certain